We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDNL
RNS Number : 6091A
Diurnal Group PLC
02 June 2021
2 June 2021
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' dealings:
Richard Ross, Chief Scientific Officer transferred 36,738 Ordinary Shares for nil consideration to a non-dependent child. Following the transaction, the total beneficial interest of Richard Ross and his wife is 2,184,355 Ordinary Shares, representing 1.3% of the total voting rights as at 2 June 2021.
Details of the full notifications received by the Company are set out below:
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Richard Ross ------------------------------- ----------------------------------------- 2 Reason for the notification -------------------------------------------------------------------------- a) Position/status Chief Scientific Officer ------------------------------- ----------------------------------------- b) Initial notification Initial notification /Amendment ------------------------------- ----------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor -------------------------------------------------------------------------- a) Name Diurnal Group plc ------------------------------- ----------------------------------------- b) LEI 213800I2HNUNZN1LDH29 ------------------------------- ----------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted -------------------------------------------------------------------------- a) Description of the Ordinary shares of 5 pence each in financial instrument, Diurnal Group plc type of instrument Identification code GB00BDB6Q760 b) Nature of the transaction Transfer of ordinary shares ------------------------------- ----------------------------------------- c) Price(s) and volume(s) ------------------------ ------------ Price(s) Volume(s) ------------------------ ------------ Nil consideration 36,738 ------------------------------------------------------------- ------------ d) Aggregated information - Aggregated volume As above - Price e) Date of the transaction 1 June 2021 ------------------------------- ----------------------------------------- f) Place of the transaction XLON ------------------------------- ----------------------------------------- For further information, please visit www.diurnal.co.uk or contact: +44 (0)20 3727 Diurnal Group plc 1000 Martin Whitaker, Chief Executive Officer Richard Bungay, Chief Financial Officer Panmure Gordon (UK) Limited (Nominated Adviser +44 (0)20 7886 and Sole Broker) 2500 Corporate Finance: Freddy Crossley, Emma Earl Corporate Broking: Rupert Dearden +44 (0)20 3727 FTI Consulting (Media and Investor Relations) 1000 Simon Conway Victoria Foster Mitchell Alex Davis
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFLFLLRDIFIIL
(END) Dow Jones Newswires
June 02, 2021 07:19 ET (11:19 GMT)
1 Year Diurnal Chart |
1 Month Diurnal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions